संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - latanoprost (unii: 6z5b6hvf6o) (latanoprost - unii:6z5b6hvf6o) - latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. teratogenic effects: pregnancy category c. reproduction studies have been performed in rats and rabbits. in rabbits, an incidence of 4 of 16 dams had no viable fetuses at a dose that was approximately 80 times the maximum human dose, and the highest nonembryocidal dose in rabbits was approximately 15 times the maximum human dose. there are no adequate and well-controlled studies in pregnant women. latanoprost ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. it is not known whether this drug or its metabolites are excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when latanoprost ophthalmic solution is administered to a nursing wom

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

aurobindo pharma limited - latanoprost (unii: 6z5b6hvf6o) (latanoprost - unii:6z5b6hvf6o) - latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. risk summary there are no adequate and well-controlled studies of latanoprost administration in pregnant women to inform drug-associated risks. in animal reproduction studies, intravenous (iv) administration of latanoprost to pregnant rabbits and rats throughout the period of organogenesis produced malformations, embryofetal lethality and spontaneous abortion at clinically relevant doses [see data] . the background risk of major birth defects and miscarriage for the indicated population is unknown. however, the background risk in the u.s. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20% of clinically recognized pregnancies. data animal data embryofetal studies were conducted in pregnant rabbits administered lat

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

somerset therapeutics, llc - latanoprost (unii: 6z5b6hvf6o) (latanoprost - unii:6z5b6hvf6o) - latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. risk summary there are no adequate and well-controlled studies of latanoprost ophthalmic solution administration in pregnant women.to inform drug-associated risks. in animal reproduction studies, intravenous (iv) administration of latanoprost to pregnant rabbits and rats throughout the period of organogenesis produced malformations, embryofetal lethality and spontaneous abortion at clinically relevant doses [see data] . the background risk of major birth defects and miscarriage for the indicated population is unknown. however, the background risk in the u.s. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20% of clinically recognized pregnancies. data animal data embryofetal studies were conducted in pregnant rabb

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - latanoprost (unii: 6z5b6hvf6o) (latanoprost - unii:6z5b6hvf6o) - latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. risk summary there are no adequate and well-controlled studies of latanoprost ophthalmic solution administration in pregnant women.to inform drug-associated risks. in animal reproduction studies, intravenous (iv) administration of latanoprost to pregnant rabbits and rats throughout the period of organogenesis produced malformations, embryofetal lethality and spontaneous abortion at clinically relevant doses [see data] . the background risk of major birth defects and miscarriage for the indicated population is unknown. however, the background risk in the u.s. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20% of clinically recognized pregnancies. data animal data embryofetal studies were conducted i

कनाडा - अंग्रेज़ी - Health Canada

mint pharmaceuticals inc - latanoprost - solution - 50mcg - latanoprost 50mcg - prostaglandin analogs

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - lantanoprost timolol maleate - eye drops solution - 50 + 5

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

bausch + lomb ireland limited - latanoprost; timolol maleate - eye drops, solution - 50mcg/ml + 5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - latanoprost 0.05 mg/ml; timolol maleate 6.8 mg/ml equivalent to timolol 5 mg/ml - eye drops, solution - 0.05mg/ml, 5mg/ml - active: latanoprost 0.05 mg/ml timolol maleate 6.8 mg/ml equivalent to timolol 5 mg/ml excipient: benzalkonium chloride dibasic sodium phosphate hydrochloric acid monobasic sodium phosphate monohydrate sodium chloride sodium hydroxide water for injection - reduction of intraocular pressure (iop) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. arrow-lattim should not be used to initiate therapy.

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

laboratoires thea - timolol; latanoprost - eye drops, solution in single-dose container - 50micrograms/ml +5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

rowex ltd - latanoprost; timolol maleate - eye drops, solution - 50mcg/ml + 5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations